Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation

Journal of Neuroscience Research

Volumn 77, Issue 5, 2004, Pages 723-729

  Sørensen, Gunnar ^a   Lindberg, Camilla ^a   Wörtwein, Gitta ^a   Bolwig, Tom G ^a   Woldbye, David P D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anxiety; NPY Y1; Rat; Sedation; Y2; Y5 receptors

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y [2 CYSTEINE]; NEUROPEPTIDE Y [26 DEXTRO HISTIDINE]; NEUROPEPTIDE Y DERIVATIVE; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; MALE; MAZE TEST; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SEDATION; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; NEUROPEPTIDE Y; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; RECEPTORS, NEUROPEPTIDE Y; TIME FACTORS;

EID: 4444346012     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20200     Document Type: Article

References (37)

1. Berglund MM, Hipskind PA, Gehlert DR. 2003. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med 228:217-244.
2. Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL. 1995. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6:215-222.
3. Cabrele C, Langer M, Bader R, Wieland HA, Doods HN, Zerbe O, Beck-Sickinger AG. 2000. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J Biol Chem 275:36043-36048.
4. Currie PJ, Coscina DV. 1996. Regional hypothalamic differences in neuropeptide Y-induced feeding and energy substrate utilization. Brain Res 737:238-242.
5. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL. 1996. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382:168-171.
6. Griebel G, Moreau GL, Jenck F, Martin JR, Misslin R. 1993. Some critical determinants of the behaviour of rats in the elevated-plus maze. Behav Proc 29:37-48.
7. Heilig M. 1995. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept 59:201-205.
8. Heilig M, Munson R. 1987. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul Pept 19:221-231.
9. Heilig M, Wahlestedt C, Widerlöv E. 1988. Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogeneity and for interaction with α-adrenoreceptors. Eur J Pharmacol 157:205-213.
10. Heilig M, Söderpalm B, Engel JA, Widerlöv E. 1989. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 98:524-529.
11. Heilig M, McLeod S, Brot M, Heinrichs ST, Menzaghi F, Koob GF, Britton KT. 1993. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8:357-363.
12. Hogg S. 1996. A review of the validity and variability of the elevated plus maze as an animal model of anxiety. Pharmacol Biochem Behav 54:21-30.
13. Kask A, Rägo L, Harro J. 1996. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur J Pharmacol 317:R3-R4.
14. Kask A, Rägo L, Harro J. 1998. Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus in rats. Brain Res 788:345-348.
15. Kask A, Nguyen HP, Pabst R, von Horsten S. 2001. Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience 104:799-806.
16. Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quirion R. 2002. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 26:259-283.
17. Katner SN, Slawecki CJ, Ehlers CL. 2002. Neuropeptide Y administration into the amygdala does not affect ethanol consumption. Alcohol 28:29-38.
18. Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E. 2001. Identification of potent and selective neuropeptide Y Y1 receptor agonists with orexigenic activity in vivo. Mol Pharmacol 60:534-540.
19. Nakajima M, Inui A, Asakawa A, Moinose K, Ueno N, Teranishi A, Baba S, Kasuga M. 1998. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 19:359-363.
20. Naveilhan P, Canals JM, Arenas E, Ernfors P. 2001a. Distinct roles of the Y1 and Y2 receptors on neuropeptide Y-induced sensitization to sedation. J Neurochem 78:1201-1207.
21. Naveilhan P, Canals JM, Valjakka A, Vartiainen J, Arenas E, Ernfors P. 2001b. Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. Eur J Neurosci 13:2241-2246.
22. Palmiter RD, Erickson JC, Hollopeter G, Baraban SC, Schwartz MW. 1998. Life without neuropeptide Y. Rec Prog Horm Res 53:163-199.
23. Pellow S, Chopin P, File SE, Briley M. 1985. Validation of open:closed arm entries in an elevated plus-maze as measure of anxiety in the rat. J Neurosci Methods 14:149-167.
24. Prut L, Belzung C. 2003. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463:3-33.
25. Redrobe JP, Dumont Y, St.-Pierre JA, Quirion R. 1999. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res 848:153-166.
26. Redrobe JP, Dumont Y, Fournier A, Quirion R. 2002. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26:615-624.
27. Redrobe JP, Dumont Y, Herzog H, Quirion R. 2003. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res 141:251-255.
28. Sajdyk TJ, Vandergriff MG, Gehlert DR. 1999. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 368:143-147.
29. Sajdyk TJ, Schober DA, Gehlert DR. 2002a. Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology 43:1165-1172.
30. Sajdyk TJ, Schober DA, Smiley D, Gehlert DR. 2002b. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav 71:419-423.
31. Smialowska M, Sopala M, Tokarski K. 1996. Inhibitory effect of intrahippocampal NPY injection on amphetamine-induced behavioural activity. Neuropeptides 30:67-71.
32. Sorensen G, Wörtwein G, Bolwig TG, Woldbye DPD. 2003. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. Soc Neurosci Abstr 539.3.
33. Thorsell A, Michalkiewicz M, Dumont Y, Quiron R, Caberlotto L, Rimondini R, Mathe AA, Heilig M. 2000. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropepride Y overexpression. Proc Natl Acad Sci U S A 97:12852-12857.
34. Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G. 2003. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 18:143-148.
35. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. 1993. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259:528-531.
36. Wolak ML, DeJoseph MR, Cator AD, Mokashi AS, Brownfield MS, Urban JH. 2003. Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry. J Comp Neurol 464:285-311.
37. Woldbye DPD, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwig TG. 1997. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med 3:761-764.